Aspex Management (HK)’s Vicarious Surgical RBOT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-86,666
| Closed | -$62K | – | 32 |
|
|
2026
Q1 | $62K | Hold |
86,666
| – | – | ﹤0.01% | 27 |
|
|
2025
Q4 | $188K | Hold |
86,666
| – | – | ﹤0.01% | 22 |
|
|
2025
Q3 | $478K | Hold |
86,666
| – | – | 0.01% | 24 |
|
|
2025
Q2 | $650K | Hold |
86,666
| – | – | 0.01% | 25 |
|
|
2025
Q1 | $569K | Hold |
86,666
| – | – | 0.01% | 28 |
|
|
2024
Q4 | $1.14M | Hold |
86,666
| – | – | 0.03% | 30 |
|
|
2024
Q3 | $492K | Hold |
86,666
| – | – | 0.01% | 28 |
|
|
2024
Q2 | $509K | Sell |
86,666
-1
| -0% | -$9 | 0.01% | 35 |
|
|
2024
Q1 | $784K | Hold |
86,667
| – | – | 0.02% | 32 |
|
|
2023
Q4 | $953K | Hold |
86,667
| – | – | 0.03% | 33 |
|
|
2023
Q3 | $1.54M | Hold |
86,667
| – | – | 0.05% | 28 |
|
|
2023
Q2 | $4.76M | Hold |
86,667
| – | – | 0.14% | 25 |
|
|
2023
Q1 | $5.9M | Hold |
86,667
| – | – | 0.15% | 30 |
|
|
2022
Q4 | $5.25M | Hold |
86,667
| – | – | 0.15% | 28 |
|
|
2022
Q3 | $8.71M | Hold |
86,667
| – | – | 0.26% | 27 |
|
|
2022
Q2 | $7.64M | Hold |
86,667
| – | – | 0.19% | 27 |
|
|
2022
Q1 | $13.2M | Hold |
86,667
| – | – | 0.52% | 20 |
|
|
2021
Q4 | $27.6M | Hold |
86,667
| – | – | 0.84% | 21 |
|
|
2021
Q3 | $38.9M | Buy |
+86,667
| New | +$27.4M | 1.3% | 19 |
|
Other funds holding RBOT
Aspex Management (HK)'s RBOT Position: Q2 2026 in Review
Aspex Management (HK) sold out of Vicarious Surgical (RBOT) in Q2 2026, closing a stake of 86,666 shares — an estimated $62K sold.
Aspex Management (HK) first reported a position in RBOT in Q3 2021 and held it in 19 quarters. The position peaked at $38.9M in Q3 2021. 1 fund tracked by Wall St. Rank holds RBOT as of Q2 2026.
- Aspex Management (HK) reported no remaining Vicarious Surgical position as of Q2 2026 after selling out during the quarter.
- Aspex Management (HK) sold 86,666 Vicarious Surgical shares in Q2 2026, an estimated $62K.
- Aspex Management (HK) first reported a position in Vicarious Surgical in Q3 2021 and held it in 19 quarters.
- Aspex Management (HK)'s Vicarious Surgical position peaked at $38.9M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vicarious Surgical as of Q2 2026.
Based on Aspex Management (HK)'s 13F filing for Q2 2026, filed 14 Aug 2026.